Effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and renal dysfunction.

Trial Profile

Effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and renal dysfunction.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure; Kidney disorders
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 09 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top